CU23939B1 - Péptidos específicos para receptores de melanocortina - Google Patents

Péptidos específicos para receptores de melanocortina

Info

Publication number
CU23939B1
CU23939B1 CU2011000227A CU20110227A CU23939B1 CU 23939 B1 CU23939 B1 CU 23939B1 CU 2011000227 A CU2011000227 A CU 2011000227A CU 20110227 A CU20110227 A CU 20110227A CU 23939 B1 CU23939 B1 CU 23939B1
Authority
CU
Cuba
Prior art keywords
melanocortin receptors
specific peptides
overweight
diabetes
disorders
Prior art date
Application number
CU2011000227A
Other languages
English (en)
Other versions
CU20110227A7 (es
Inventor
John H Dodd
Yi-Qun Shi
Wei Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CU20110227A7 publication Critical patent/CU20110227A7/es
Publication of CU23939B1 publication Critical patent/CU23939B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)

Abstract

La invención se refiere a péptidos cíclicos específicos para receptores de melanocortina de Fórmula (I) o una sal farmacéuticamente aceptable de los mismos, donde R1, R2, R3, R4a, R4b, R4c, R5 x e y son como se definen en la memoria descriptiva. Estos compuestos son particularmente útiles en el tratamiento de enfermedades, trastornos y/o afecciones relacionados con la homeostasis de la energía y el metabolismo (por ejemplo, diabetes), relacionados con la ingesta de alimentos y/o relacionados con el equilibrio de energía y el peso corporal, incluidos la obesidad, el sobrepeso y enfermedades, trastornos y/o afecciones asociados con la obesidad y/o el sobrepeso, tales como la diabetes tipo 2 y el síndrome metabólico.
CU2011000227A 2009-06-08 2011-12-08 Péptidos específicos para receptores de melanocortina CU23939B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18493209P 2009-06-08 2009-06-08
PCT/SE2010/050626 WO2010144038A1 (en) 2009-06-08 2010-06-07 Melanocortin receptor-specific peptides

Publications (2)

Publication Number Publication Date
CU20110227A7 CU20110227A7 (es) 2012-06-21
CU23939B1 true CU23939B1 (es) 2013-08-29

Family

ID=43301172

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000227A CU23939B1 (es) 2009-06-08 2011-12-08 Péptidos específicos para receptores de melanocortina

Country Status (27)

Country Link
US (4) US8455617B2 (es)
EP (1) EP2440569B8 (es)
JP (2) JP5615353B2 (es)
KR (1) KR20120039614A (es)
CN (2) CN103833832A (es)
AR (1) AR077011A1 (es)
AU (1) AU2010259278B2 (es)
BR (1) BRPI1010613A2 (es)
CA (1) CA2764797A1 (es)
CL (1) CL2011003095A1 (es)
CO (1) CO6480936A2 (es)
CU (1) CU23939B1 (es)
DO (1) DOP2011000380A (es)
EA (1) EA201190325A1 (es)
EC (1) ECSP11011507A (es)
HN (1) HN2011003218A (es)
IL (1) IL216451A0 (es)
MX (1) MX2011013173A (es)
NI (1) NI201100213A (es)
NZ (1) NZ596556A (es)
PE (2) PE20120408A1 (es)
SA (1) SA110310492B1 (es)
SG (1) SG176127A1 (es)
TW (1) TW201102082A (es)
UY (1) UY32690A (es)
WO (1) WO2010144038A1 (es)
ZA (1) ZA201200128B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
CA3301962A1 (en) 2011-12-29 2026-03-02 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
WO2013134376A1 (en) * 2012-03-06 2013-09-12 Vanderbilt University Positive allosteric modulators for melanocortin receptors
US10196425B2 (en) * 2013-03-15 2019-02-05 Rhythm Pharmaceuticals, Inc. Peptide compositions
PT2970389T (pt) * 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PT3356386T (pt) 2015-09-30 2024-05-17 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados à via do receptor da melanocortina-4
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US11174298B2 (en) * 2016-11-09 2021-11-16 James P. Tam Preparation and use of ginsentides and ginsentide-like peptides
CN107880111B (zh) * 2017-11-14 2021-02-05 浙江湃肽生物有限公司 一种制备利拉鲁肽的方法
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
US11505575B2 (en) 2018-06-21 2022-11-22 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
IL321719A (en) 2018-06-21 2025-08-01 Merck Sharp ַ& Dohme Llc Pcsk9 antagonist compounds
EP3810177B1 (en) 2018-06-21 2024-12-04 Ra Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246386A1 (en) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Cyclic polypeptides for pcsk9 inhibition
WO2019246352A1 (en) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Pcsk9 antagonist bicyclo-compounds
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
WO2021041770A1 (en) * 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
AU2021217939A1 (en) * 2020-02-03 2022-09-15 Palatin Technologies, Inc. Reverse amide-linked melanocortin receptor-specific cyclic peptides
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
ATE109793T1 (de) 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
WO1998027113A2 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
DK1165613T3 (da) 1999-03-29 2008-08-25 Procter & Gamble Melanocortinreceptorligander
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US6693165B2 (en) 2000-01-18 2004-02-17 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
PL366630A1 (en) 2000-08-30 2005-02-07 F.Hoffmann-La Roche Ag Selective cyclic peptides
NZ524190A (en) 2000-09-27 2004-09-24 Procter & Gamble Melanocortin receptor ligands
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
CA2453515A1 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US6960646B2 (en) 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
WO2004046166A2 (en) 2002-11-14 2004-06-03 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US20050101535A1 (en) 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
CA2523408A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A\S Peptides for use in treating obesity
CN1784423A (zh) * 2003-05-09 2006-06-07 诺沃挪第克公司 用于治疗肥胖的肽
KR20060026011A (ko) * 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
JP2006527772A (ja) 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
AU2004251616A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
CN100398536C (zh) 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
MXPA06003474A (es) 2003-09-30 2006-06-05 Novo Nordisk As Agonistas de receptores de melanocortina.
CA2547083C (en) 2003-11-24 2019-05-14 Clinuvel Pharmaceuticals Limited A method of inducing melanogenesis in humans with mc1r variant alleles
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2575866C (en) 2004-08-04 2018-07-10 Clinuvel Pharmaceuticals Limited Methods for inducing melanogenesis in a subject
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
CN101076348A (zh) 2004-10-08 2007-11-21 克里纽沃药物有限公司 用于在受试者中诱导黑素原生成的组合物和方法
ATE501731T1 (de) 2004-10-25 2011-04-15 Centocor Ortho Biotech Inc Melanocortin-rezeptor-bindende mimetibodies, zusammensetzungen, verfahren und verwendungen
US20080306008A1 (en) 2004-11-04 2008-12-11 Nova Nordisk A/S Peptides for Use in the Treatment of Obesity
CN101052650A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
WO2006048450A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treating obesity
EP1809665A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
US20080207493A1 (en) 2005-03-17 2008-08-28 Novo Nordisk A/S Compounds for Use in the Treatment of Obesity
CN101203527A (zh) 2005-05-31 2008-06-18 耶路撒冷希伯来大学伊森姆研究发展公司 主链环化的促黑皮质素激素（αMSH）类似物
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
KR100997177B1 (ko) 2005-07-08 2010-11-29 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
CA2616583A1 (en) 2005-07-18 2007-01-25 Novo-Nordisk A/S Peptides for use in the treatment of obesity
WO2007027574A2 (en) 2005-08-29 2007-03-08 Palatin Technologies, Inc. Cyclic peptide isolation by spray drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
EP2106407A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2104684A1 (en) 2007-01-18 2009-09-30 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
CN101302246B (zh) 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
US20090076029A1 (en) 2007-06-01 2009-03-19 Palatin Technologies, Inc. Compounds and Methods for Treating Obesity
US20090081197A1 (en) 2007-06-01 2009-03-26 Palatin Technologies, Inc. Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
TW201002340A (en) 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
WO2009152079A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides

Also Published As

Publication number Publication date
BRPI1010613A2 (pt) 2016-03-15
US8455617B2 (en) 2013-06-04
MX2011013173A (es) 2012-04-02
SA110310492B1 (ar) 2013-12-18
EP2440569A4 (en) 2012-12-05
ECSP11011507A (es) 2012-01-31
TW201102082A (en) 2011-01-16
CN102459312B (zh) 2015-05-06
EP2440569B8 (en) 2017-03-01
AU2010259278A1 (en) 2011-12-08
AU2010259278B2 (en) 2014-06-05
CO6480936A2 (es) 2012-07-16
JP2014111637A (ja) 2014-06-19
US9040663B2 (en) 2015-05-26
WO2010144038A1 (en) 2010-12-16
ZA201200128B (en) 2012-09-26
UY32690A (es) 2011-01-31
CU20110227A7 (es) 2012-06-21
AR077011A1 (es) 2011-07-27
US20120046219A1 (en) 2012-02-23
EP2440569A1 (en) 2012-04-18
CN102459312A (zh) 2012-05-16
SG176127A1 (en) 2011-12-29
EP2440569B1 (en) 2016-08-24
KR20120039614A (ko) 2012-04-25
US20150252077A1 (en) 2015-09-10
CL2011003095A1 (es) 2012-06-22
DOP2011000380A (es) 2012-02-15
US20130237473A1 (en) 2013-09-12
PE20150878A1 (es) 2015-06-24
PE20120408A1 (es) 2012-05-25
JP5615353B2 (ja) 2014-10-29
CN103833832A (zh) 2014-06-04
NI201100213A (es) 2012-08-03
JP2012529505A (ja) 2012-11-22
IL216451A0 (en) 2012-01-31
NZ596556A (en) 2014-04-30
US20100311648A1 (en) 2010-12-09
EA201190325A1 (ru) 2012-06-29
US8455618B2 (en) 2013-06-04
HN2011003218A (es) 2014-11-10
CA2764797A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
UY32690A (es) Péptidos específicos para receptores de melanocortina
PE20151178A1 (es) Analogos de glucagon
EA201490982A1 (ru) Аналоги глюкагона
CL2014001587A1 (es) Combinacion farmaceutica, composicion farmaceutica o kit farmaceutico que comprenden un inhibidor de dpp-4 y un analogo de glp-1; metodo para tratar y/o prevenir la obesidad o el sobrepesoo para reducir el peso corporal en un paciente humano.
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
ECSP12011593A (es) Análogos de glucagón acilados
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
AR091422A1 (es) Analogos peptidicos de la exendina 4
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
MX2013002453A (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
BR112013029269A8 (pt) combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2
MX2016006577A (es) Uso de composiciones nutritivas que tienen una cantidad baja de proteina.
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
MX344303B (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
UA109414C2 (uk) Арильовані камфени та фармацевтична композиція на їх основі
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
CR20110657A (es) Péptidos específicos para receptores de melanocortina
TH135805A (th) เปปไทด์ที่จำเพาะต่อมีลาโนคอร์ติน รีเซพเตอร์
PE20141576A1 (es) Combinacion terapeutica de memantina y baclofeno y composicion farmaceutica que los contiene
TH143143A (th) วิธีและองค์ประกอบที่มีประโยชน์สำหรับชักนำให้สัตว์นอนหลับ
CO6382136A2 (es) Análogos de glucagón

Legal Events

Date Code Title Description
FG Grant of patent